When confined to a primary site (early stage disease), the five-year survival rate from colon cancer is ϳ90%. However, when disseminated from primary sites (metastatic), survival drops precipitously to 8%. These dramatic survival statistics underscore the need to define the pathobiology of the metastatic process to devise novel interventions to prevent or inhibit colon cancer spread. Hematogenous metastasis occurs as a highly regulated cascade of events, initiated by the escape of tumor cells from the primary site into the blood stream and culminating in the formation of secondary colonies in distant organs. This process critically involves the binding of circulating colon cancer cells to the endothelium of target tissue(s) under fluid shear conditions, as well as the dynamic formation of leukocyte/cancer cell emboli, each of which are directed by selectin-selectin ligand interactions.The selectin family of adhesion molecules, E-, P-, and L-selectin, are Ca 2ϩ -dependent lectins that bind sialofucosylated carbohydrate structures, the prototypes of which are sialyl Lewis X (sLe x ) and sialyl Lewis A (sLe a ) (1, 2). E-and P-selectin are typically inducible endothelial molecules (P-selectin is also expressed on activated platelets), and L-selectin expression is restricted to leukocytes (3). There are multiple reports that tumor cell expression of E-selectin ligand(s) promotes the metastatic spread of numerous cancer types in vivo, including colon cancer (4 -10). Colon carcinoma cells also tether and roll under dynamic flow conditions on E-selectin purified and immobilized on plastic (11, 12), as well as E-selectin presented by cytokine-stimulated human umbilical vein endothelial cells (HUVEC) 2 (11-13). Independently, L-selectin has been shown to promote colon cancer metastasis in vivo (14), presumably mediated by the physical association of leukocytes with tumor cells resulting in leukocyte-colon cancer cell emboli (15, 16). Although expression of E-selectin ligand(s) on tumor cells itself promotes metastasis, one model holds that selectins work cooperatively to promote the spread of cancer; leukocyte L-selectin engagement of relevant tumor ligand(s) mediates the formation of leukocyte-tumor aggregates, which possess heightened binding capacity to endothelium in an E-selectindependent manner (16).Colon carcinoma cells express selectin ligands, and there is abundant evidence that selectin-dependent adhesive events are central to the metastatic process (4 -10,14). However, these selectin ligands have yet to be fully characterized or identified other than by general classifications (e.g. mucins). We recently identified the sialofucosylated hematopoietic cell E-and L-selectin ligand (HCELL) glycoform of CD44 on the LS174T colon carcinoma cell line and demonstrated its function as a high affinity E-and L-selectin ligand using the blot rolling assay (17, 18). However, these studies did not specifically address the relative contribution(s) of HCELL to the observed potent E-and L-selectin ligand activity of intact LS174...